Brensocatib AZD-7986
【Chemical Name】Brensocatib
【Original】Astrazeneca
【Time to market】phase III
【Dosage and Usage】used to treat bronchiectasis and coronavirus infection
Brensocatib AZD-7986
一、 Product Overview
Brensocatib is a small molecule drug developed by Astrazeneca and is a CTSC inhibitor. At present, the highest stage of research and development of this drug is the phase III of clinical trials, which is used to treat bronchiectasis and coronavirus infection.
二、Main products
Description | Structural Formula | CAS No. | Category |
Brensocatib |  | 1802148-05-5 | API |
5-chloro-3-methylbenzo[d]oxazol-2(3H)-one |
| 5790-90-9 | intermediates |
tert-butyl (S)-(1-amino-3-(4-bromophenyl)-1-oxopropan-2-yl)carbamate |
| 869569-99-3 | intermediates |
(S)-4-(tert-butoxycarbonyl)-1,4-oxazepane-2-carboxylic acid |
| 1273567-44-4 | intermediates |
tert-butyl (S)-(1-amino-3-(4-iodophenyl)-1-oxopropan-2-yl)carbamate |
| 868694-44-4 | intermediates |
3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazol-2(3H)-one |
| 1220696-32-1 | intermediates |
tert-butyl (S)-(1-cyano-2-(4-iodophenyl)ethyl)carbamate |
| 1159489-37-8 | intermediates |
Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement and its liability is at buyer's risk.